Format

Send to

Choose Destination
Nat Rev Mol Cell Biol. 2012 Nov;13(11):713-26. doi: 10.1038/nrm3448. Epub 2012 Oct 4.

Induced pluripotent stem cells: the new patient?

Author information

1
Department of Anatomy and Embryology, Leiden University Medical Center, Leiden, The Netherlands.

Abstract

Worldwide increases in life expectancy have been paralleled by a greater prevalence of chronic and age-associated disorders, particularly of the cardiovascular, neural and metabolic systems. This has not been met by commensurate development of new drugs and therapies, which is in part owing to the difficulty in modelling human diseases in laboratory assays or experimental animals. Patient-specific induced pluripotent stem (iPS) cells are an emerging paradigm that may address this. Reprogrammed somatic cells from patients are already applied in disease modelling, drug testing and drug discovery, thus enabling researchers to undertake studies for treating diseases 'in a dish', which was previously inconceivable.

PMID:
23034453
DOI:
10.1038/nrm3448
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center